Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -214,085 | -122,931 | -581,599 | -450,986 | -344,545 |
| Depreciation Amortization | 8,599 | 4,319 | 19,479 | 13,818 | 9,385 |
| Accounts receivable | N/A | N/A | 25,000 | 25,000 | 25,000 |
| Other Working Capital | -19,107 | -15,409 | 71,882 | 49,245 | 38,336 |
| Other Operating Activity | 32,198 | 25,124 | 120,224 | 110,462 | 103,997 |
| Operating Cash Flow | $-192,395 | $-108,897 | $-345,014 | $-252,461 | $-167,827 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -768,135 | -553,330 | 3,107 | -33,907 | -13,964 |
| PPE Investments | -1,152 | -504 | -914 | -397 | -323 |
| Purchase Of Investment | -13,343 | -4,615 | -9,700 | -9,700 | -9,700 |
| Sale Of Investment | 318,701 | 147,706 | 702 | N/A | 99,209 |
| Other Investing Activity | -2,473 | 0 | -25,000 | -25,000 | -25,000 |
| Investing Cash Flow | $-466,402 | $-410,743 | $-31,805 | $-69,004 | $50,222 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 600,000 | 600,000 | N/A | N/A | N/A |
| Common Stock Issued | 13,738 | 5,436 | 426,026 | 309,612 | 12,846 |
| Other Financing Activity | -14,650 | -13,528 | 0 | 0 | 0 |
| Financing Cash Flow | $599,088 | $591,908 | $426,026 | $309,612 | $12,846 |
| Exchange Rate Effect | -26 | -32 | 95 | 94 | 121 |
| Beginning Cash Position | 359,078 | 359,078 | 309,776 | 309,776 | 309,776 |
| End Cash Position | 299,343 | 431,314 | 359,078 | 298,017 | 205,138 |
| Net Cash Flow | $-59,735 | $72,236 | $49,302 | $-11,759 | $-104,638 |
| Free Cash Flow | |||||
| Operating Cash Flow | -192,395 | -108,897 | -345,014 | -252,461 | -167,827 |
| Capital Expenditure | -1,152 | -504 | -914 | -397 | -323 |
| Free Cash Flow | -193,547 | -109,401 | -345,928 | -252,858 | -168,150 |